Paul Gehret, working in a Philadelphia lab, held in his hands a fragile, translucent scaffold—no bigger than a child’s pinky nail—that could one day help thousands of infants breathe freely. This tiny structure, engineered from decellularized meniscal cartilage and seeded with ear-derived cells, represents a breakthrough in treating severe subglottic stenosis, a life-threatening narrowing of the airway that affects an estimated 20,000 infants in the U.S. each year. For decades, the standard treatment has been laryngotracheal reconstruction using rib cartilage grafts, but many young children simply don’t have enough of it, delaying surgery and leaving them dependent on tracheostomy tubes. Now, researchers at Children’s Hospital of Philadelphia (CHOP), led by Riccardo Gottardi, Ph.D., and Ian Jacobs, MD, have pioneered a new approach that could change that reality. Their innovation—called MEND, for MENiscus Decellularization—removes cells, elastin, and blood vessels from donor meniscal tissue, leaving behind a biocompatible scaffold that can be repopulated with a patient’s own ear-derived cartilage progenitor cells (eCPCs). These cells mature into chondrocytes, effectively regenerating functional cartilage in less than four weeks. That speed is critical: in infants, surgeons often have just a one- to two-month window to intervene before developmental delays or complications set in. Unlike traditional engineered cartilage, which can take up to six months to grow, MEND slashes that timeline dramatically. In preclinical models, the MEND grafts not only integrated seamlessly with surrounding tissue but outperformed rib cartilage grafts, with no adverse events reported. The implications extend beyond airway repair—this method could one day be adapted for joint repairs, craniofacial reconstruction, or other pediatric cartilage needs. While human trials are still on the horizon, the data so far suggests a future where infants no longer wait months for a piece of themselves to grow in a lab. Instead, they might receive a personalized, off-the-shelf-ready graft that acts like native tissue, grows with them, and avoids the pain of harvesting rib cartilage. As Gottardi puts it, the goal has always been to create something that “behaves like native tissues and regrows and is part of the airway.” Now, that vision is closer than ever.